News from the healthcare data industry
April 20, 2022 From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change. Pharm Exec: How…
April 20, 2022 In an interview with Targeted Oncology, Luv Hajirawala, MD, discussed the relevance of high-risk features in patients with stage III colon cancer, and how a recent real-world analysis may change risk stratification in the future. For patients with stage III colon cancer, prognostics based on risk category…
April 20, 2022 07:00 ET | Source: Tonix Pharmaceuticals Holding Corp. Over 40% of Long COVID Patients Had Fibromyalgia-Like Multi-Site Pain Symptoms Rate of Opioid Use in Long COVID Patients with Multi-Site Pain is a Potential Health Concern CHATHAM, N.J., April 20, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP),…
You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in your inbox every Tuesday and Thursday. Investigating an FDA program for medtech innovation In a constantly-growing pool of innovative medical technologies, what does it take…
By Sean Hilscher, vice president, Greenleaf Health The FDA’s release of four draft guidances on real-world evidence (RWE) at the tail end of 2021 is a productive step toward implementing FDA’s RWE program. The draft guidances are expansive, providing recommendations to sponsors seeking to use real-world data (RWD) derived from…
HYDERABAD, India and BOSTON, Mass., April 19, 2022 /PRNewswire/ — Excelra, a leading global Data and Analytics provider for Life Science organizations, has announced a strategic majority investment in Anlitiks, a young and rapidly growing technology company in the value and evidence domain. The investment reinforces Excelra’s push into the Health Economics and Outcomes Research…
Abstract Daratumumab monotherapy was first investigated in GEN501 and SIRIUS trials in relapsed/refractory multiple myeloma (RRMM) patients, showing positive results. However, there is a lack of information on plasmacytoma response. We described a real-world study of 43 RRMM patients who received daratumumab monotherapy. The overall response rate (ORR) was 26%,…
Centers for Disease Control and Prevention Continues Critical Work to Modernize Data ManagementApril 15, 2022 06:59 AM Eastern Daylight Time DENVER–(BUSINESS WIRE)–Palantir Technologies Inc. (NYSE:PLTR) today announced an extension and expansion of its work with the U.S. Centers for Disease Control and Prevention (CDC) through the outbreak response and disease…
April 14, 2022 06:59 AM Eastern Daylight Time DENVER–(BUSINESS WIRE)–Palantir Technologies Inc. (NYSE: PLTR) today announced that it will unveil a new suite of products available within the Palantir Apollo platform. The company will present these products at an Apollo Demo Day on Wednesday, April 27, 2022 at 11:00 am…
CHICAGO and SCOTTSDALE, Ariz., April 14, 2022 /PRNewswire/ — EVERSANA™, the pioneer of next-generation commercial services to the global life sciences industry, and UpScriptHealth™, the leading telehealth and virtual prescribing platform serving life sciences companies, today announced a strategic partnership to create a direct-to-patient platform that will transform the patient experience to help accelerate access to therapies…